Why the study?
Catheter ablation for atrial fibrillation carries a 2-3% risk of hemorrhage or thromboembolic complications, making optimal periprocedural anticoagulation schemes critical to minimize adverse events.
This review highlights the importance of periprocedural anticoagulation strategies, including uninterrupted oral anticoagulation and reversal agents, to minimize bleeding and thromboembolic complications during atrial fibrillation ablation.
Underscores caution with periprocedural anticoagulation in AF ablation; leaves optimal strategies open for randomized trials.
Catheter ablation is a standard treatment for patient with symptomatic and drugrefractory atrial fibrillation. As for every invasive approach, ablation is associated with certain risk of complications. About 2-3% of adverse events are related to hemorrhage or thromboembolism. Therefore, periprocedural anticoagulation scheme is of paramount importance to minimize the risk of both types of complications. Here we describe the factors, associated with thromboembolic and bleeding risks, and the evolving approaches for periprocedural anticoagulation treatment. Special attention is paid to uninterrupted oral anticoagulation and potential role of reverse agent in management of procedure-related hemorrhages.
No takes yet. Share an insight, caveat, or question.
Gasymova et al. (2019) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: